DIA Europe 2018 | SCHEDULE

Monday, 16 April 2018

13:00-18:00	Registration Hours
14:00-17:30	Short Courses - See Final Programme page 15 to 17

Tuesday, 17 April 2018

07:00-17:00	Registration Hours		
09:00-10:30	Swissmedic/WHO Signature Session - Montreal	IMI PREFER Satellite Session - Singapore	09:00-12:30 Short Courses - See Final Programme page 15 to 17
10:30-11:00	Coffee Break in the Exhibition Hall		
11:00-12:30	DIAmond Session: EU Regulatory Town Hall - EMA Relocation and Implications for Centralised Activities - Montreal	DIAmond Session: Payer Town Hall - Singapore	DIAmond Session: International Pharmacovigilance - Sydney
12:30-14:00	Lunch Break in the Exhibition Hall		13:00-13:45 CAT Spotlight - Kairo 1-2 13:00-13:45 EFPIA Spotlight - Boston 1-2
14:00-15:30	DIAmond Session: Realising the Potential of Future Biomedical Innovation: The Role of Intensified EU Cooperation on HTAs - Singapore	DIAmond Session: Will Big Data Change Drug Development's Approach? - Montreal	China FDA Topics - Kairo 1-2 DIAlogue: First-in-Human Guideline 13:00 - 15:30 - Shanghai 1-2
15:30-16:00	Coffee Break in the Exhibition Hall		
16:00-19:30	Conference Keynote Session (San Francisco) followed by the Welcome Reception		

Wednesday, 18 April 2018

	A	B	C	D	E	F	G	H	I			
Topic	Can Regulators and HTA Bodies Create Synergies for Patient Access?	What are Necessary Steps towards Outcome-Driven Health Systems?	Medicines of the Future: What Will Innovation Need and Bring?	How Can Better Outcomes Be Enabled by Big Data?	What is the Future of Pharmacovigilance?	What Can Stakeholders Expect from Clinical Trial (Development), Transparency and Medical Information?	A New Era for Medical Devices and Diagnostics. How Is The Impact?	Drug Development and Regulatory Approval - Reference Points around the Globe or Globalisation?	How Can We Enable Clinical Research in Europe Further?	Hot Topics/Stand-Alone Sessions	Hot Topics/Stand-Alone Sessions / External	Content Hub/Engage and Exchange/ Spotlight
08:00-17:00	Registration Hours											
08:30-10:00	DIAmond Session: Evidence Generation in Medicines Development for Fragmented and Rare Patient Populations - Sydney			DIAmond Session: Exploring Use of Artificial Intelligence: Trust in Technology, or Trust in Each Other? - Boston 1-2				DIAmond Session: Patient-Centricity Beyond the Talk - Singapore			Session 1100 NCA Showcase: Brexit Implications for the EU 27 Network and Decentralised Activities - Montreal	
10:00-10:30	Coffee Break in the Exhibition Hall											
10:30-12:00	Session 0101 Collaboration across Decision Makers to Facilitate Patient Access Recent Advances and Future Needs - Singapore	Session 0201/0401 Has the Time for Big/Real World Data Finally Arrived? - Delhi	Session 0301 Novel Therapeutic Approaches - Shanghai 1-2	Session 0201/0401 Has the Time for Big/Real World Data Finally Arrived - Delhi	Session 0501 Enhancing Benefit-Risk Management through the Product Life Cycle - Sydney	Session 0601 EMA Proactive Transparency – Clinical Data Publication (Policy 0070) - Boston 1-2	Session 0701 IVD Regulation and the Upcoming Changes in Regulatory Landscape - Boston 3	Session 0801 Update on PMDA's Activities - Shanghai 3	Session 0901 New European Clinical Trial Regulation: A New Paradigm with Major Impact on Clinical trial Stakeholders - Montreal	Session 1001 Fighting the Fakes – Preparing for Upcoming EU Medicine Serialisation - Kairo 1-2	Session 1101 Learnings from the First 10 years of the Paediatric Regulation – Back to Inform on the Future? - Darwin	Content Hubs - Innovation Theatre 10:30-11:00 Endpoints in Clinical Research 11:15-11:45 Less than Perfect? Clinical Efficacy Data Supporting Approval of New Drugs: Focus on Approvals Based on a Single Pivotal Trial
12:00-14:00	Lunch Break in the Exhibition Hall											12:30-13:30 ADAPT SMART Spotlight - Shanghai 3 12:30-13:30 TransCelerate Spotlight - Boston 3
14:00-15:15	Session 0102 Regulatory Access Pathways to Facilitate Early Access, HTA Synergies - Singapore	Session 0202 Patient Centricity – What does it Really Mean? - Sydney	Session 0302 Digital Health - What is the Landscape Looking Like for Medicines? - Shanghai 1-2	Session 0402 New Collaboration Models with Regulators and Patients - Boston 3	Session 0502 Innovative Approaches to Safety Information - Montreal	Session 0602 Data Sharing and Secondary Use of Data - Boston 1-2	Session 0702 Regulatory – How to Submit a Combination Product or Drug Device Combination Globally - Darwin	Session 0802 Paediatric Policy Initiatives: Globalisation of Paediatric Drug Development Best Practice or Imperialism of Practice? - Shanghai 3	Session 0902 Registry Studies: What Are the Expectations from the Regulators? - Delhi	Session 1002 ICMRA – The Future of Medicines and Challenges for International Regulators - Kairo 1-2		Content Hubs - Innovation Theatre 14:00-14:30 Enabling and Constraining Factors in Commercial ATMP Development 14:45-15:15 Key Learnings from the First European Patient Advocacy Advisory Board for Leber's Hereditary Optic Neurotherapy
15:15-16:00	Coffee Break in the Exhibition Hall											E&E: 15:15-16:00 TransCelerate - Foyer, Level 2
16:00-17:30	Session 0103 Enhancing Evidence Generation across the Product Life Cycle - Sydney	Session 0203 Health Economics of Future Therapeutic Concepts - Shanghai 3	Session 0303 The New Data Ecology - How to Incentivise and Enable More Sharing of Data? - Lima	Session 0403 Needed Competencies for Big Data - Learning from Other Industries - Singapore	Session 0503 Measuring Impact of Pharmacovigilance in the EU - Montreal	Session 0603 Drawing the Boundaries of Data Disclosure in Clinical Trials - Delhi	Session 0703 Challenges in the Current Regulatory Landscape Considering FDA and MDR Expectations - Boston 3	Session 0803 Reliance and Work Sharing @ Work - State of Play and Hands-On Experience - Kairo 1-2	Session 0903 Novel and Innovative Clinical Trial Designs: From Adaptive/ Seamless Designs to the Trial of the Future - Boston 1-2	Session 1003 Russia and the Eurasian Union – Regulatory Challenges and Opportunities - Shanghai 1-2		Content Hubs - Innovation Theatre 16:00-16:30 Drivers, Barriers and Benefits of a Unified Clinical Operating Model 16:45-17:15 The Master's Data Management from the 'Single Place of Truth'
17:30-18:30	Networking Reception in the Exhibition Hall											

Thursday, 19 April 2018

08:00-13:00	Registration Hours											
08:30-10:00	Session 0104 ATMPs - Singapore	Session 0204 Value and Access- How Do We Strike a Balance between Both? - Sydney	Session 0304 Collaborative Frameworks and Public Private Partnerships as Drivers of Innovation - Boston 3	Session 0404 Overview of Major Big Data Projects across EU, US, Japan - Kairo 1-2	Session 0504 Five Years On - PV Legislation Delivers on Long-Promised Elements - Montreal	Session 0604 EMA Proactive Transparency – Clinical Data Publication (Policy 0070) - Boston 1-2	Session 0704 Life Cycle Management Activities of Drug Device Combinations - Lima	Session 0804 GMP Convergence – A Key Part of Regulatory System Strengthening - Shanghai 3	Session 0904 Smarter Clinical Trials Thanks to Real World Data - Delhi	Session 1004 ICH Info Day Part 1 - Shanghai 1-2	Session 1104 DIAlogue: Unmet Need in Regulatory and Pricing Decision Making - Darwin	Content Hubs - Innovation Theatre 09:15-09:45 How Partnering with the Regulatory Intelligence Function Enables Innovative Regulatory and Drug Development Strategies
10:00-10:30	Coffee Break in the Exhibition Hall											
10:30-12:00		Session 0205 Sustainability of Health Care Funding - Are We Prepared for Tomorrow's Funding Challenge? - Delhi	Session 0305 Precision Medicine and Personalised Health Care - Sydney	Session 0405 Big Data Mandates Strict Data Governance - Kairo 1-2	Sesison 0505 Benefit/Risk Communication Tools that Work: Towards a Tailor-Made Drug Facts Box? - Montreal	Session 0605 The Promise and Reality of Clinical Trial Transparency Initiativese - Singapore	Session 0705 Impact of Human Factors on the Development of Combination Products - Boston 3	Session 0805 Lifecycle Management – The Unknown Barrier to Access - Shanghai 3	Session 0905 ICH Info Day Part 2 - Shanghai 1-2	Session 1005 Key Initiatives in Europe to Walk the Talk in Patient - Focused Medicines Development - Boston 1-2	Session 1105 Turkish Regulatory Session - Darwin	
12:00-13:00	Lunch Break in the Exhibition Hall											
13:00-14:30	Conference Insights and Outcomes - Rapid Fire Session - Sydney											